Edgewise Therapeutics Eyes Key Data Readouts in 2026 for Becker Muscular Dystrophy and Cardiomyopathy Programs
Event summary
- Edgewise Therapeutics expects 12-week data from CIRRUS-HCM trial for EDG-7500 in hypertrophic cardiomyopathy (HCM) in H1 2026.
- Pivotal GRAND CANYON trial results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026.
- Phase 1 trial data for EDG-15400 in heart failure expected in H1 2026.
- Cash position stood at $530.1 million as of December 31, 2025.
The big picture
Edgewise Therapeutics is positioning itself as a key player in the treatment of rare muscle diseases and cardiovascular conditions, with multiple near-term catalysts that could validate its pipeline. The company's focus on Becker muscular dystrophy and hypertrophic cardiomyopathy addresses significant unmet medical needs, potentially differentiating it in a competitive biopharmaceutical landscape. The financial stability provided by its substantial cash reserves positions Edgewise to execute on its strategic goals without immediate funding pressures.
What we're watching
- Regulatory Pathway
- Whether the GRAND CANYON trial results will support a successful NDA submission for sevasemten in Becker muscular dystrophy in H1 2027.
- Clinical Development
- The pace at which Edgewise can advance EDG-7500 into Phase 3 trials for hypertrophic cardiomyopathy following Part D data in H1 2026.
- Financial Runway
- How Edgewise will allocate its $530.1 million cash position to support multiple late-stage programs through potential regulatory milestones.
Related topics